News | August 19, 2015

Edge Therapeutics Reports Positive Top-Line Phase 1/2 NEWTON Trial Results of EG-1962 in Aneurysmal Subarachnoid Hemorrhage – Efficacy results show 60% favorable outcome vs. only 28% for standard of care – EG-1962 met primary and secondary safety endpoint...

News | August 18, 2015

Intarcia Announces New Top-Line Phase 3 Results for Investigational Therapy ITCA 650 in Type 2 Diabetes: Freedom-2 Comparative Trial Demonstrates Superior & Sustained Glucose Control and Weight Reduction vs Januvia Over 52 Weeks • Patients treated with ITCA 650...

News | August 18, 2015

WAVE Life Sciences Raises $66 Million in Series B Financing – Genetic medicine company continues to expand breadth of potential therapeutic applications for novel stereopure synthetic chemistry platform to treat rare diseases – Pipeline to span multiple...

News | August 11, 2015

QPID Health to Deploy at Providence Health & Services Health system to implement QPID Health to support quality improvement initiatives Boston – August 11, 2015 – QPID Health, which helps hospitals and medical groups complete quality and registry reporting more...

News | August 10, 2015

Relypsa Enters Two-Year Detailing Agreement With Sanofi in the United States REDWOOD CITY, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) — Relypsa Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced it has entered a two-year detailing agreement with Sanofi...
libero mattis diam nec Nullam libero